<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197767</url>
  </required_header>
  <id_info>
    <org_study_id>13-006694</org_study_id>
    <nct_id>NCT02197767</nct_id>
  </id_info>
  <brief_title>Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis</brief_title>
  <official_title>A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is being done to see if the study medication, Rituximab, preserves kidney
      function after 12 months of taking the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label pilot study to determine if the use of Rituximab reduces
      proteinuria over a 12 month period and is there preservation of kidney function with the use
      of this study drug. Each patient will be treated with 2 intravenous infusions of rituximab
      1000 mg, two weeks apart for a total of 2 doses. Each patient will be retreated with
      identical 2 intravenous infusions of rituximab, two weeks apart at 6 months after the first
      infusion, irrespective of cluster of differentiation (CD) 20+ cell counts. Thus, each
      participant will receive 4 infusions of rituximab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24 Hour Creatinine Clearance</measure>
    <time_frame>Day 0, Day 365</time_frame>
    <description>Change in 24 hour creatinine clearance with the use of rituximab at 12 months. Creatinine clearance results are reported as milliliters/minute/patient's body surface area (mL/min/SA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Proteinuria</measure>
    <time_frame>Day 0, Day 365</time_frame>
    <description>Change in proteinuria in milligrams (mg) with the use of rituximab at 12 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Fibrillary Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>1000 mg infusion</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fibrillary Glomerulonephritis with diagnostic biopsy performed within the last 2 years

          -  Proteinuria &gt;1 gram

          -  Age &gt; 18 years but &lt; 80 years

          -  Adequately controlled blood pressure (BP&lt;140/90 mmHg in &gt;75% of the readings) for at
             least 3 months prior to enrollment with the use of (angiotensin converting enzyme
             inhibitors (ACEi) and/or angiotensin-receptor blockers (ARB), if tolerated.

          -  Women must be post- menopausal, surgically sterile or practicing a medically approved
             method of contraception

          -  Able and willing to give written informed consent and comply with the requirements of
             the study protocol

          -  Adequate renal function as indicated by estimated glomerular filtration rate (GFR) &gt;
             25 mL/min using the Chronic Kidney Disease Epidemiology Collaboration (CKD/EPI)
             formula or a quantified creatinine clearance &gt;25 mL/min, and/or serum creatinine &lt;3.0
             mg/dL in the presence of ACEi/ARB therapy

          -  Adequate bone marrow function, as indicated by hemoglobin &gt;7.0 gm/dL, white count &gt;3.0
             x 10(9), platelet count &gt;100 x 10(9)

          -  Negative chest x-ray within one year

          -  Negative serum pregnancy test (for women of child bearing age)

          -  Normal organ function.

          -  Subject agrees to use an acceptable method of birth control during treatment and for
             twelve months after completion of treatment

          -  Subject has provided written informed consent

          -  Subject agrees to discontinue routine use of non-steroidal anti-inflammatory drugs

          -  Absolute Neutrophil Count (ANC): &gt; 1000/ mm3

          -  Adequate liver function, as indicated by aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), alkaline phosphatase and total bilirubin &lt; 2x upper limit or
             normal unless related to primary disease

          -  Negative HBsAg and anti-hepatitis B (HBc) lab values within 1 year of signing consent

        Exclusion Criteria:

          -  Pregnancy (determined by a serum pregnancy test for all women of childbearing
             potential within 7 days of treatment), or lactating.

          -  Inability to comply with study and/or follow-up procedures

          -  History of HIV (a documented positive lab value within one year of enrollment)

          -  Presence of active infection

          -  New York Heart Association Classification III or IV heart disease

          -  Concomitant malignancies or previous malignancies within the last five years, with the
             exception of adequately treated basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  History of psychiatric disorder

          -  At the Investigator's discretion, receipt of a live vaccine within 4 weeks prior to
             randomization

          -  At the Investigator's discretion, positive Hepatitis C serology

          -  Known history of diabetes mellitus or a Hemoglobin A1c result &gt; 6.0% within 90 days
             prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen B. Erickson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <results_first_submitted>January 16, 2019</results_first_submitted>
  <results_first_submitted_qc>January 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2019</results_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Stephen B. Erickson, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>fibrillary glomerulonephritis</keyword>
  <keyword>rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>MabThera</keyword>
  <keyword>Zytuxâ„¢</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02197767/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab</title>
          <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
rituximab: 1000 mg infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab</title>
          <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
rituximab: 1000 mg infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 24 Hour Creatinine Clearance</title>
        <description>Change in 24 hour creatinine clearance with the use of rituximab at 12 months. Creatinine clearance results are reported as milliliters/minute/patient's body surface area (mL/min/SA).</description>
        <time_frame>Day 0, Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
rituximab: 1000 mg infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24 Hour Creatinine Clearance</title>
          <description>Change in 24 hour creatinine clearance with the use of rituximab at 12 months. Creatinine clearance results are reported as milliliters/minute/patient's body surface area (mL/min/SA).</description>
          <units>mL/min/SA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="15.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.072</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Proteinuria</title>
        <description>Change in proteinuria in milligrams (mg) with the use of rituximab at 12 months.</description>
        <time_frame>Day 0, Day 365</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
rituximab: 1000 mg infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proteinuria</title>
          <description>Change in proteinuria in milligrams (mg) with the use of rituximab at 12 months.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2589.8" spread="1741.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the duration of the study until 30 days following the last administration of study treatment or study discontinuation/termination, whichever was earlier.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rituximab</title>
          <description>rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
rituximab: 1000 mg infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen B. Erickson</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-4083</phone>
      <email>Erickson.Stephen@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

